Based on Margaret Atwood’s award-winning novel of the same name, 'The Testaments' is set years after the events of 'The ...
Gilead and Arcellx reported promising data for their CAR-T therapy anito-cel at the annual American Society of Hematology ...
The 2025 meeting of the American Society of Hematology features some of the newest developments in blood cancers and rare ...
Gilead Sciences' Kite unit has showcased three new CAR-T therapies at ASH, headed by multiple myeloma candidate ...
Gilead is hoping to break ground early next year on its Chess Hatch campus as part of its plans to expand its presence in ...
Hulu has unveiled a first look at “The Testaments,” the upcoming sequel series to “The Handmaid’s Tale.” The series, which is ...
Swedish biotech Sprint Bioscience is selling off an early-stage TREX1 cancer program to Gilead for $14 million upfront, plus ...
Gilead Sciences stock has seen its fair value estimate edge down only slightly, from about $130.83 to $130.63, even as the ...
Zacks Investment Research on MSN
Investors heavily search Gilead Sciences, Inc. (GILD): Here is what you need to know
Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...
Hulu releases first images from The Testaments, highlighting June’s daughter Agnes and introducing new characters ...
Kite, a Gilead Company, has presented new findings demonstrating the safety, efficacy and quality of life benefits offered by ...
The Fierce team will be out of office next Friday for the Thanksgiving holiday. The next edition of Chutes & Ladders will publish Dec. 5. | Gilead’s general counsel and EVP of corporate affairs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback